Short-Course Regimens by Dr Jay Achar, TB referent, Médecins Sans Frontières, Operational Center Amsterdam
Short-Course Regimens by Dr Jay Achar, TB referent, Médecins Sans Frontières, Operational Center Amsterdam
Off label use: Bedaquilline beyond 24 weeks by Dr Lorenzo Guglielmetti , Medical doctor, Bligny Hospital, Paris
Off label use: Bedaquilline beyond 24 weeks by Dr Lorenzo Guglielmetti , Medical doctor, Bligny Hospital, Paris
Combination of Bedaquilline and Delamanid: from theory to practice by Dr Jennifer Furin, Lecturer at the Department of Global Health & Social Medicine, Harvard Medical School
Combination of Bedaquilline and Delamanid: from theory to practice by Dr Jennifer Furin, Lecturer at the Department of Global Health & Social Medicine, Harvard Medical School
Children under 18 year old with Dlm or Bdq by Dr Jennifer Furin, Lecturer at the Department of Global Health & Social Medicine, Harvard Medical School
Children under 18 year old with Dlm or Bdq by Dr Jennifer Furin, Lecturer at the Department of Global Health & Social Medicine, Harvard Medical School
Children under 18 year old with Dlm or Bdq by Dr Sylvie Jonckheere, Project medical referent, Médecins Sans Frontières, India
Children under 18 year old with Dlm or Bdq by Dr Sylvie Jonckheere, Project medical referent, Médecins Sans Frontières, India
Children under 18 year old with Dlm or Bdq by Dr Ia Urtkmelidze, TB Pediatrician, National Center for Tuberculosis and Lung Diseases (NCTLD), Georgia
Children under 18 year old with Dlm or Bdq by Dr Ia Urtkmelidze, TB Pediatrician, National Center for Tuberculosis and Lung Diseases (NCTLD), Georgia
Children under 18 year old with Dlm or Bdq by Dr Alan Adler, Medical Doctor, Médecins Sans Frontières, Tajikistan
Children under 18 year old with Dlm or Bdq by Dr Alan Adler, Medical Doctor, Médecins Sans Frontières, Tajikistan
Clinical trials update by Dr Carole Mitnick, Associate professor at the Department of Global Health & Social Medicine, Harvard Medical School
Clinical trials update by Dr Carole Mitnick, Associate professor at the Department of Global Health & Social Medicine, Harvard Medical School
Clinical trials update by Dr Bern-Thomas Nyang’wa, Project Manager and Chief Investigator of TB PRACTECAL, Médecins Sans Frontières UK
Clinical trials update by Dr Bern-Thomas Nyang’wa, Project Manager and Chief Investigator of TB PRACTECAL, Médecins Sans Frontières UK
Implementing policies to improve patient quality of care
Treatment of TB amongst migrant populations by Dr Maira Zhaparkulova, Medical coordinator of Ministry of Health, Kazakhstan
Treatment of TB amongst migrant populations by Dr Maira Zhaparkulova, Medical coordinator of Ministry of Health, Kazakhstan
WHO policies implementation by Dr Grania Brigden, TB Advisor, Médecins Sans Frontières’ Access Campaign, Geneva
WHO policies implementation by Dr Grania Brigden, TB Advisor, Médecins Sans Frontières’ Access Campaign, Geneva
New WHO guidelines in the pipeline by Dr Fuad Mirzayev, Medical Officer of Laboratories, Diagnostics & Drug Resistance Unit of the Global TB program, World Health Organization, Geneva
New WHO guidelines in the pipeline by Dr Fuad Mirzayev, Medical Officer of Laboratories, Diagnostics & Drug Resistance Unit of the Global TB program, World Health Organization, Geneva
Improving patient's experience of TB treatment
Adherence: where there is hope by Beverly Collin Stringer, Health Policy and Research Advisor, Médecins Sans Frontières UK
Adherence: where there is hope by Beverly Collin Stringer, Health Policy and Research Advisor, Médecins Sans Frontières UK
Counselling: what role in national programs and how to improve patient support by Dr Alena Skrahina, Deputy Director of the National TB Program, Belarus
Counselling: what role in national programs and how to improve patient support by Dr Alena Skrahina, Deputy Director of the National TB Program, Belarus
Civil society: practical role in improving TB outcomes and supporting patients and programs by Elchin Mukhtarli, “Saglamliga Khidmat” public union, Azerbaijan
Civil society: practical role in improving TB outcomes and supporting patients and programs by Elchin Mukhtarli, “Saglamliga Khidmat” public union, Azerbaijan
Dr Eka Sanikidze, Director of TB patient Union, Georgia
Dr Eka Sanikidze, Director of TB patient Union, Georgia
Patient association groups: what role in DRTB treatment programs? By Zamirbek Boronbaev & Kholdaraly Zakbarov, TB patient association, Kyrgyzstan
Patient association groups: what role in DRTB treatment programs? By Zamirbek Boronbaev & Kholdaraly Zakbarov, TB patient association, Kyrgyzstan
Improving patient's experience of TB treatment
Ambulatory treatment from day 1 by Dr Gulzira Nurullaeva, Medical Doctor, Médecins Sans Frontières, Uzbekistan
Ambulatory treatment from day 1 by Dr Gulzira Nurullaeva, Medical Doctor, Médecins Sans Frontières, Uzbekistan
Ambulatory care: how to adapt treatment delivery at home by Dr Hakob Atchemyan, Research assistant, Médecins Sans Frontières, Armenia
Ambulatory care: how to adapt treatment delivery at home by Dr Hakob Atchemyan, Research assistant, Médecins Sans Frontières, Armenia
Other approaches to patient delivery models by Dr Saghit Bektasov, Head of Medical Department, National Center for Tuberculosis, Kazakhstan
Other approaches to patient delivery models by Dr Saghit Bektasov, Head of Medical Department, National Center for Tuberculosis, Kazakhstan
Delivery methods for new drugs : Video DOT by Dr Naira Khachatryan, Deputy medical coordinator, Médecins Sans Frontières, Armenia
Delivery methods for new drugs : Video DOT by Dr Naira Khachatryan, Deputy medical coordinator, Médecins Sans Frontières, Armenia
Diagnostics and monitoring to improve patient quality of care
How will pharmacovigilance (PV) help us manage our patients? By Dr Svetlana Setkina, Deputy Head of Republican Pharmacological Laboratory, National TB Program, Belarus
How will pharmacovigilance (PV) help us manage our patients? By Dr Svetlana Setkina, Deputy Head of Republican Pharmacological Laboratory, National TB Program, Belarus
How will pharmacovigilance (PV) help us manage our patients? By Dr Nino Lomtadze, Head of surveillance and strategic planning department, National Center for Tuberculosis and Lung Diseases, Georgia
How will pharmacovigilance (PV) help us manage our patients? By Dr Nino Lomtadze, Head of surveillance and strategic planning department, National Center for Tuberculosis and Lung Diseases, Georgia
DST to new drugs, early detection of eligible patients - Elisa Ardizzoni , Mycobacteriologist at Mycobacteriology Unit of Institute of Tropical Medicine of Antwerp, Belgium
DST to new drugs, early detection of eligible patients - Elisa Ardizzoni , Mycobacteriologist at Mycobacteriology Unit of Institute of Tropical Medicine of Antwerp, Belgium
Monitoring of comorbidities: the example of diabetes - Dr Animesh Sinha, Medical Activity Manager, Médecins Sans Frontières, Operational Center Amsterdam
Monitoring of comorbidities: the example of diabetes - Dr Animesh Sinha, Medical Activity Manager, Médecins Sans Frontières, Operational Center Amsterdam
Participants List in English
List of Participants
Patients and TB: Improving treatment outcomes through a patient centred approach and access to new treatments
The Ministry of Labour , Health and Social Affairs of Georgia and the international medical organization Médecins Sans Frontières/ Doctors Without Borders (MSF) are pleased to welcome the participants and guests attending the 5th Regional Tuberculosis Symposium for Central Asia and Eastern Europe, which will take place in Tbilisi on 22d and 22d March 2016.
This scientific forum is bringing together a delegation of 180 participants and speakers: representatives from the Ministries of Health of the region, experts from MSF as well as other national and international organizations and donor agencies such as the World Health Organization and the Global Fund, among others.
The symposium will focus on “Patients and TB: Improving treatment outcomes through a patient centred approach and access to new treatments”. It aims at sharing information and experiences on new developments in the fight against tuberculosis, and particularly against the drug-resistant forms of the disease (DR-TB), which are a public health concern in the region.
“This scientific forum gives the opportunity to the international and local experts, TB specialists and involved parties to share their experiences and discuss the challenges”, said Dr. Valeri Kvaratskhelia, Deputy Minister of Health of Georgia, in his welcome message to participants. “Georgia was one of the first countries to introduce the new TB drugs. [Today], the Ministry is planning to modify the National Tuberculosis Program and updating of the National TB Strategy, in order to maintain the results of the investment already made and improving the outcomes of TB treatment”.
“This symposium re-affirms the commitment of MSF to work with countries in the region and find new, more effective ways to tackle DR-TB”, says Dr. Sylvie Goossens, MSF representative in Georgia. “In recent years, MSF has been helping patients to gain access to new drugs that can save their lives. Now we intend to increase their number, run clinical research of new regimens, and continue working with our partners to simplify the treatments and make them easier to bear for patients”.
TB Symposium 2016 - Introduction:
march 30, 2016
Introduction by Dr Mario Raviglione, Director of the Global TB Programme, World Health Organization.
Out of step
TB Policies in 24 countries
November 2015